Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study-Reference-Cited by-同舟云学术

Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study

Published:2004-05 Issue:9423 Volume:363 Page:1751-1756
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Mamdani Muhammad,Juurlink David N,Lee Douglas S,Rochon Paula A,Kopp Alex,Naglie Gary,Austin Peter C,Laupacis Andreas,Stukel Therese A

Publisher

Elsevier BV

Subject

General Medicine

Reference23 articles.

1. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study—a randomized controlled trial;Silverstein;JAMA,2000

2. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis;Bombardier;N Engl J Med,2000

3. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs;Mamdani;BMJ,2002

4. Risk of cardiovascular events associated with selective COX-2 inhibitors;Mukherjee;JAMA,2001

5. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease;Ray;Lancet,2002

Cited by 369 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetes in axial spondyloarthritis: a systematic review and meta-analysis of observational studies;Rheumatology International;2024-09-12

2. Emerging Roles and Therapeutic Applications of Arachidonic Acid Pathways in Cardiometabolic Diseases;Circulation Research;2024-06-21

3. When cardiovascular medicines should be discontinued;European Heart Journal;2024-06-05

4. Eurasian Association of Cardiology (EAC)/ National Society of Heart Failure And Myocardial Disease (NSHFMD) guidelines for the diagnosis and treatment of chronic heart failure (2024);Eurasian heart journal;2024-05-27

5. Vulnerable period in heart failure: a window of opportunity for the optimization of treatment – a statement by Mexican experts;Drugs in Context;2024-01-16